ZINFORO 600 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION
How to use ZINFORO 600 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet:information for the user
Zinforo600mg powder for concentrate for solution for infusion
ceftaroline fosamil
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Zinforo and what is it used for
- What you need to know before you use Zinforo
- How to use Zinforo
- Possible side effects
- Storage of Zinforo
- Contents of the pack and other information
1. What is Zinforo and what is it used for
What is Zinforo
Zinforo is an antibiotic medicine that contains the active substance ceftaroline fosamil. It belongs to a group of medicines called “cephalosporin antibiotics”.
What is Zinforo used for
Zinforo is used to treat children (from birth) and adults with:
- skin and soft tissue infections
- a lung infection called “pneumonia”
How Zinforo works
Zinforo works by killing certain bacteria that can cause serious infections.
2. What you need to know before you use Zinforo
Do not use Zinforo
- if you are allergic to ceftaroline fosamil or any of the other ingredients of this medicine (listed in section 6)
- if you are allergic to cephalosporins (a class of antibiotics)
- if you have had severe allergic reactions to other antibiotics such as penicillin or carbapenem.
Do not use Zinforo if any of the above applies to you. If you are not sure, talk to your doctor or nurse before using Zinforo.
Warnings and precautions
Talk to your doctor or nurse before starting Zinforo:
- if you have kidney problems (your doctor may need to prescribe a lower dose)
- if you have ever had seizures (epileptic fits or convulsions)
- if you have ever had a non-severe allergic reaction to other antibiotics such as penicillin or carbapenem
- if you have had severe diarrhea when taking antibiotics in the past.
You may get another infection caused by another bacterium during or after treatment with Zinforo.
You may develop signs and symptoms of severe skin reactions such as fever, joint pain, skin rash, scaly red rash, skin bumps containing pus, blisters, or peeling of the skin, circular red patches often with blisters in the center on the trunk, ulcers in the mouth, throat, nose, genitals, and eyes. If this happens, talk to your doctor or nurse immediately.
Lab tests
You may develop an abnormal response to a lab test (called Coombs test) that detects certain antibodies that can act against red blood cells. If your red blood cell count decreases, your doctor may check if these antibodies have caused this decrease in red blood cells.
If any of the above applies to you (or you are not sure), talk to your doctor or nurse before using Zinforo.
Other medicines and Zinforo
Tell your doctor or nurse if you are using, have recently used, or might use any other medicines.
Pregnancy and breastfeeding
If you are pregnant, talk to your doctor before using Zinforo. Do not use this medicine during pregnancy unless your doctor has told you to.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
Zinforo may cause side effects such as dizziness. This may affect your ability to drive or use machines.
3. How to use Zinforo
Zinforo will be given to you by a doctor or nurse.
How much to use
The recommended dose for adults is 600 mg every 12 hours. Your doctor may increase your dose to 600 mg every 8 hours for some infections. The recommended dose for children depends on the child's age and weight and is given every 8 or 12 hours. It is given through a drip into a vein over 5 to 60 minutes if you receive the standard dose or 120 minutes if you receive a higher dose.
A treatment cycle usually lasts from 5 to 14 days for skin infections and 5 to 7 days for pneumonia.
Patients with kidney problems
If you have kidney problems, your doctor may reduce your dose, as Zinforo is removed from your body through your kidneys.
If you use more Zinforo than you should
If you think you have been given too much Zinforo, tell your doctor or nurse immediately.
If you miss a dose of Zinforo
If you think you have missed a dose, tell your doctor or nurse immediately.
If you have any other questions about using this medicine, ask your doctor or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:
Tell your doctor immediately if you get any of these symptoms, as you may need urgent medical treatment:
- Sudden swelling of your face, lips, tongue, or throat; a severe rash; and problems swallowing or breathing. These can be signs of a severe allergic reaction (anaphylaxis) and can be life-threatening;
- Diarrhea that becomes severe or doesn't stop, or stools that contain blood or mucus during or after stopping treatment with Zinforo. In this situation, do not take medicines that stop or slow down bowel movements.
Very common (may affect more than 1 in 10 people)
- Changes in a blood test called “Coombs test” commonly seen in patients taking this type of antibiotic. This test detects certain antibodies that can act against your red blood cells.
Common (may affect up to 1 in 10 people)
- Fever
- Headache
- Feeling dizzy
- Itching, skin rash
- Diarrhea, stomach pain
- Nausea or vomiting
- Increased production of liver enzymes (detected in blood tests)
- Pain and irritation of the veins
- Redness, pain, or swelling at the injection site.
Uncommon (may affect up to 1 in 100 people)
- Anemia
- Raised itchy rash (urticaria)
- An increase in creatinine levels in the blood. Creatinine indicates how well your kidneys are working
- Bleeding or bruising more than usual. This may be due to a decrease in platelet count in the blood
- Changes in tests that determine how your blood clots
- A decrease in the total number of white blood cells, or a certain type of white blood cells in the blood (leucopenia and neutropenia).
- Changes in your mental state, such as confusion, reduced level of consciousness, abnormal movements, or seizures (encephalopathy): these have occurred in people when the dose given is too high, especially in people with kidney problems.
Rare (may affect up to 1 in 1,000 people)
- A significant decrease in the number of certain white blood cells in the blood (agranulocytosis). You may get a fever, symptoms similar to flu, sore throat, or other infections that could be serious.
- An increase in the number of certain white blood cells in the blood (eosinophilia).
Frequency not known (cannot be estimated from the available data)
- A type of lung disease where eosinophils (a type of white blood cell) appear in the lungs in larger numbers (eosinophilic pneumonia).
Sudden chest pain, which may be a sign of a potentially serious allergic reaction, called Kounis syndrome, which has been seen with other medicines of the same type. If this happens, talk to a doctor or nurse immediately.
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Zinforo
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton. The expiry date is the last day of the month stated.
Store below 30°C.
Keep in the original packaging to protect from light.
Medicines should not be disposed of via wastewater or household waste. The hospital will dispose of all waste materials safely. This will help protect the environment.
6. Contents of the pack and other information
What Zinforo contains
- Each vial contains 600 mg of ceftaroline fosamil.
- The other ingredient is arginine.
Appearance and packaging
Zinforo is a pale yellowish-white to yellow powder for concentrate for solution for infusion in a vial. It is available in packs containing 10 vials.
Marketing authorisation holder
Pfizer Ireland Pharmaceuticals Unlimited Company
Operations Support Group
Ringaskiddy, County Cork
Ireland
Manufacturer
ACS Dobfar S.p.A.
Via A. Fleming 2
37135 Verona
Italy
You can request more information about this medicine from the local representative of the marketing authorisation holder:
België/Belgique/Belgien Luxembourg/Luxemburg Pfizer NV/SA Tél/Tel: +32 (0)2 554 62 11 | Latvija Pfizer Luxembourg SARL filiale Latvija Tel: +371 670 35 775 |
България Пфайзер България ЕООД Тел.: +359 2 970 4333 | Lietuva Pfizer Luxembourg SARL filialas Lietuvoje Tel. +3705 2514000 |
Ceská republika Pfizer, spol. s r.o. Tel: +420-283-004-111 | Magyarország PFIZER Kft. Tel. + 36 1 488 37 00 |
Danmark Pfizer ApS Tlf.: +45 44 20 11 00 | Malta Vivian Corporation Ltd. Tel: +35621 344610 |
Deutschland PFIZER PHARMA GmbH Tel: +49 (0)30 550055-51000 | Nederland Pfizer bv Tel: +31 (0)800 63 34 636 |
Eesti Pfizer Luxembourg SARL Eesti filiaal Tel: +372 666 7500 | Norge Pfizer AS Tlf: +47 67 52 61 00 |
Ελλάδα Pfizer ΕΛΛΑΣ Α.Ε. Τηλ.: +30 210 67 85 800 | Österreich Pfizer Corporation Austria Ges.m.b.H. Tel: +43 (0)1 521 15-0 |
España Pfizer, S.L. Tel: +34 91 490 99 00 | Polska Pfizer Polska Sp. z o.o. Tel.: +48 22 335 61 00 |
France Pfizer Tél: +33 (0)1 58 07 34 40 | Portugal Laboratórios Pfizer, Lda. Tel: +351 21 423 5500 |
Hrvatska Pfizer Croatia d.o.o. Tel: + 385 1 3908 777 | România Pfizer România S.R.L. Tel: +40 (0)21 207 28 00 |
Ireland Pfizer Healthcare Ireland Unlimited Company Tel: +1800 633 363 (toll free) +44 (0)1304 616161 | Slovenija Pfizer Luxembourg SARL Pfizer, podružnica za svetovanje s podrocja farmacevtske dejavnosti, Ljubljana Tel: + 386 (0)1 52 11 400 |
Ísland Icepharma hf. Sími: +354 540 8000 | Slovenská republika Pfizer Luxembourg SARL, organizacná zložka Tel: +421–2–3355 5500 |
Italia Pfizer S.r.l. Tel: +39 06 33 18 21 | Suomi/Finland Pfizer Oy Puh./Tel: +358 (0)9 430 040 |
Κύπρος Pfizer ΕΛΛΑΣ Α.Ε. (CYPRUS BRANCH) Τηλ: +357 22 817690 | Sverige Pfizer AB Tel: +46 (0)8 550 520 00 |
Date of last revision of this leaflet: 01/2025.
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu.
---------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Important: Consult the summary of product characteristics before prescribing.
Aseptic technique must be used to prepare the infusion solution. The contents of the Zinforo vial should be reconstituted with 20 ml of water for injections. The following are the instructions for reconstituting the Zinforo vial:
Dose concentration (mg) | Volume of diluent to add (ml) | Approximate concentration of ceftaroline (mg/ml) | Amount to withdraw |
600 | 20 | 30 | Total volume |
The reconstituted solution must be further diluted to produce the Zinforo infusion solution. A 250 ml, 100 ml, or 50 ml infusion bag can be used to prepare the infusion, based on the required patient volume. Suitable diluents for infusion include: sodium chloride 9 mg/ml (0.9%) solution for injection, dextrose 50 mg/ml (5%) solution for injection, sodium chloride 4.5 mg/ml and dextrose 25 mg/ml solution for injection (0.45% sodium chloride and 2.5% dextrose), or Ringer's lactate solution. The resulting solution should be administered over 5 to 60 minutes for the standard dose or 120 minutes for the high dose in infusion volumes of 50 ml, 100 ml, or 250 ml.
The infusion volumes for pediatric patients will vary according to the child's weight. The concentration of the infusion solution during preparation and administration should not exceed 12 mg/ml of ceftaroline fosamil.
The reconstitution time is less than 2 minutes. Mix slowly to reconstitute and check to ensure the contents have dissolved completely. Parenteral drugs should be inspected visually for particles before administration.
The color of the Zinforo infusion solutions ranges from clear, pale yellow to dark yellow depending on concentration and storage conditions. It is free from particles. When stored as recommended, the potency of the product is not affected.
Chemical and physical stability in use has been demonstrated for up to 12 hours at 2 - 8 °C and 6 hours at 25 °C.
From a microbiological point of view, the product should be used immediately unless the opening/reconstitution/dilution method precludes the risk of microbial contamination. If not used immediately, in-use storage times and conditions before use are the responsibility of the user.
The compatibility of Zinforo with other medicines has not been established. Zinforo should not be mixed or physically added to solutions containing other drugs.
Each vial is for single use only.
Disposal of unused medicine and all materials that have come into contact with it should be done in accordance with local regulations.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to ZINFORO 600 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTIONDosage form: INJECTABLE PERFUSION, 600 mgActive substance: ceftaroline fosamilManufacturer: Qilu Pharma Spain S.L.Prescription requiredDosage form: INJECTABLE PERFUSION, 1 gActive substance: cefiderocolManufacturer: Shionogi B.V.Prescription requiredDosage form: INJECTABLE PERFUSION, 1 g/0.5 gActive substance: ceftolozane and beta-lactamase inhibitorManufacturer: Merck Sharp & Dohme B.V.Prescription required
Online doctors for ZINFORO 600 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION
Discuss questions about ZINFORO 600 MG POWDER FOR CONCENTRATE FOR PERFUSION SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
